Skip to main content
Fig. 1 | Neurological Research and Practice

Fig. 1

From: Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis

Fig. 1

SARS-CoV-2 specific ELISpot and IgG responses in patients with multiple sclerosis (MS) and matched healthy controls (HC). a ELISpot responses to spike (S), b to membrane (M) and nucleocapsid (NC) and c IgG antibody responses against S1. Horizontal bold lines indicate median values, dashed lines the cutoff for positive responses (3 spots increment or antibody ratio of 1.1). S1: peptide mix of the SARS-CoV-2 spike (S) 1; S1/S2: peptide mix of the spike (S) 1 and S2; S Sino: S1 protein; M: peptide mix of the membrane; NC: peptide mix of the nucleocapsid. ***p < 0.0001 (Mann–Whitney test)

Back to article page

Neurological Research and Practice

ISSN: 2524-3489

Contact us